Although the treatment landscape for small cell lung cancer has hardly changed in decades, new possibilities are emerging. Long-term data from KEYNOTE-604 support incorporating immune checkpoint inhibition up front, as this provides durable benefit. A bispecific T-cell engager and other combination therapies also show signs of potential as second- or later-line therapies.

You do not currently have access to this content.